Clinical Trial of an Omicron-Targeting Vaccine Is Ready to Begin

As Americans’ COVID-19 fatigue continues to grow, Pfizer announced it will begin a clinical trial on a COVID-19 vaccine designed to target the highly transmissible Omicron variant of SARS-CoV-2. Pfizer’s original two-dose COVID-19 vaccine has not been as effective as preventing infection with the Omicron variant as it was against the Delta variant. The trial, conducted in the United States, will test a three-dose regimen on volunteers who are unvaccinated and a third dose among those who have already completed the initial two-dose regimen. For those who have already received a booster shot of the Pfizer series, the effectiveness of a fourth booster will also be evaluated. The trial will include 1,400 participants. Click here to read more.